arrow
C

Christoph Schliemann

universitätsklinikum münster
H指数:45
被引数:6,079

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukaemia patients: A multicentre real-world study

吉列替尼与异基因造血干细胞移植序贯治疗复发/难治FMS样酪氨酸激酶3(FLT3)突变急性髓系白血病患者的多中心真实世界研究

2026-09-050
OAAI
Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1/2 trial

维奈克拉联合高剂量阿糖胞苷和米托蒽醌作为复发或难治性急性髓系白血病(RELAX)的挽救治疗:一项多中心、单臂、Ⅰ/Ⅱ期试验

2026-03-040
OAAI
Trabectedin plus CD13-targeted tissue factor tTF-NGR against advanced relapsed or refractory soft tissue sarcoma: translational data, clinical safety and efficacy

曲贝替定联合靶向CD13的组织因子tTF-NGR治疗晚期复发或难治性软组织肉瘤:转化数据、临床安全性和有效性

2026-02-190
OAAI
Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction Therapy
2026-01-010
OAAI
Pretransplant HMA and Venetoclax in AML patients – a Real-World Analysis from the Cooperative Transplant Study Group

移植前HMA和Venetoclax在AML患者中的应用——来自合作移植研究组的真实世界分析

2025-12-150
OAAI
Relapse after allogeneic hematopoietic stem cell transplantation in patients with active acute myeloid leukemia

异基因造血干细胞移植后活动性急性髓系白血病患者的复发

2025-12-010
OAAI
Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients

4978例接受强化治疗的AML欧洲患者队列中,髓系发育异常相关基因突变的不同预后影响

Leukemia
IF13.4
2025-10-270
OA
Rapid epigenomic classification of acute leukemia

急性白血病的快速表观基因组分类

2025-09-220
OAAI
Immune reconstitution in AML and MDS patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) with treosulfan- or TBI-based conditioning

接受曲奥舒凡或TBI为基础预处理方案的异基因造血细胞移植(allo-HCT)的AML和MDS患者的免疫重建

2025-08-220
OAAI
Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial

疾病风险而非缓解状态决定了AML的移植结局:ASAP试验的长期结局

Blood
IF23.1
2025-08-050
OAAI
Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis

吉姆单抗奥佐米星在CBF-AML一线治疗中的应用:一项回顾性多中心分析的见解

Leukemia
IF13.4
2025-07-210
OA
Induction chemotherapy with CPX-351 in acute myeloid leukemia: revisiting the role of early bone marrow assessment

CPX-351在急性髓系白血病中的诱导化疗:重新评估早期骨髓评估的作用

Leukemia
IF13.4
2025-07-030
OAAI
High-dose melphalan followed by busulfan and fludarabine conditioning prior to allogeneic stem cell transplantation in elderly patients with active AML – a retrospective single center study

大剂量美法仑后接白消安和氟达拉滨预处理,用于老年活动性急性髓系白血病患者异基因干细胞移植——一项回顾性单中心研究

2025-06-010
OAAI
Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III study

首次完全缓解的老年急性髓性白血病患者的造血细胞移植: 一项随机III期研究的结果

2024-08-081
OAAI
Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens
2024-04-241
OAAI
Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence
2024-03-206
OAAI